ABOUT US

Pioneering the Future of Genome Editing

Editact Therapeutics is pioneering novel, first-in-class “one-for-many” CRISPR genome editing solutions to familial diseases. Our innovation is rooted in and has been licensed from the Hong Kong University of Science and Technology.

Internationally Recognised Technology

The core technologies carried by Editact Therapeutics have won the Major Neuroscience Breakthroughs of 2021 in China, the first in the Greater Bay Area, and the Gold Medal in the 49th International Exhibition of Inventions in Geneva in April 2024. Editact Therapeutics has also secured the RAISe+ scheme funding from the HKSAR Innovation and Technology Commission in 2024. 

 

Our platform employs advanced genome editing technologies designed to deliver precise therapies tailored to neurological disorders. By harnessing cutting-edge techniques, we are positioned to make significant advancements in the treatment landscape, ultimately benefiting a broader patient population.

  • Our Vision

    To pioneer a global revolution in genome editing for unprecedented solutions to incurable familial diseases. To shatter the boundaries of health, offering a new lease on life for humanity.

  • Our Mission

    To harness the power of scientific breakthroughs and cutting-edge technology to eliminate familial Alzheimer’s disease and other inherited diseases at their core. With unwavering dedication, we strive to instil hope and enhance the quality of life for individuals and families grappling with these devastating conditions. We are committed to rewriting the future of healthcare.​ 

  • Our Goal

    To accelerate the transition from laboratory discovery to clinical application, establishing a strong therapeutic pipeline that targets high-impact genetic diseases. Through collaborations, talent cultivation and scientific excellence, we strive to create a lasting global health impact.

Editact Therapeutics is rapidly advancing a robust therapeutic pipeline built on its proprietary genome editing platform. Our research programs are strategically developed to ensure precision, scalability and safety – empowering the next generation of curative treatments for genetic disorders.